TOP - May 2018, Vol 11, No 1

Based on the available data, the question still remains as to whether nivolumab plus ipilimumab provides a significant OS benefit compared with nivolumab monotherapy.

In 2 separate studies, apalutamide (Erleada) and enzalutamide (Xtandi) reduced the risk for metastasis and prolonged metastasis-­free survival in patients with nonmetastatic castrate-resistant prostate cancer (CRPC), according to the results of 2 clinical trials presented at the 2018 Genitourinary Cancers Symposium.

According to Dr Tsai, the length of optimal treatment can vary from patient to patient, but treatment discontinuation studies and longer follow-up periods are needed before definitive recommendations can be incorporated into survivorship care plans.

Interim data from a recent clinical trial of nelipepimut-S plus trastuzumab showed a disease-free survival advantage compared with trastuzumab alone in patients with HER2 1+/2+ breast cancer.

In the May issue of The Oncology Pharmacist, we feature highlights of key presentations and studies from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, which took place in Denver, CO.

At the 2018 Hematology/Oncology Pharmacy Association Annual Conference, Dr Seddon provided attendees with an overview of FLT3-mutated AML, including currently available treatments, mechanisms of resistance, and future directions.

PD-L1 is decidedly unique when compared with other biomarkers currently used in oncology, and the impact of PD-L1 expression has been demonstrated in numerous clinical scenarios.

POUT was one of the most often tweeted clinical trials from the meeting, where it was met with much praise. “It is a triumph getting behind a trial with a low-incidence tumor. UTUC is a relatively rare disease, and it is safe to say it is more lethal than muscle-invasive bladder cancer.

Although it is very curable when found and treated early on, early-stage cervical cancer may not cause any noticeable signs or symptoms.

Progression-free survival (PFS) was extended by 3.5 months with first-line atezolizumab (Tecentriq) plus bevacizumab (Avastin) in patients with metastatic renal-­cell carcinoma (RCC) versus standard-of-care sunitinib (Sutent) in the phase 3 IMmotion151 clinical trial presented at the 2018 Genitourinary Cancers Symposium

Page 1 of 2
Results 1 - 10 of 11